Drugs / GNOS-PV02
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04251117 | Mar 2020 → Nov 2024 overdue | hepatocellular carcinoma | Geneos Therapeutics | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07722741 | Sep 2026 → Sep 2029 expected | hepatocellular carcinoma | Geneos Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2024-04-07 | Geneos Therapeutics | Results Geneos Therapeutics Announces Positive Phase 1/2 Data for GT-30 Trial of Personalized Therapeutic Cancer Vaccine geneostx.com ↗
The study met its primary endpoints of safety and immunogenicity and its secondary endpoint of efficacy based on observed response rate (ORR). |
| 2023-08-22 | Geneos Therapeutics | Results Geneos Therapeutics Announces Eight of 34 Patients to Achieve Complete Response, Complete Molecular Response, or, Secondary Resectability in Ongoing Clinical Trial of Personalized Therapeutic Cancer Vaccination in Second Line Advanced Liver Cancer geneostx.com ↗
To date, among 32 evaluable patients from the first 34 enrolled, by RECIST1.1 the study has achieved 3 complete responses, 7 partial responses, 9 stable disease and 13 progressive disease. |
| 2022-12-14 | Geneos Therapeutics | Results Geneos Therapeutics Announces Another Complete Response in Ongoing Clinical Trial of Personalized Therapeutic Cancer Vaccination in Second Line Advanced Liver Cancer geneostx.com ↗
Overall response rate by RECIST 1.1 is 30.4% in the evaluable patients consisting of three complete responses, four partial responses, six stable disease, and ten progressive disease. |
| 2022-11-07 | Geneos Therapeutics | Results Geneos Therapeutics Announces Positive Clinical Data for Personalized Therapeutic Cancer Vaccines in Ongoing Liver Cancer Trial geneostx.com ↗
Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced positive safety and efficacy data from the first 24 patients (23 evaluable) enrolled in GT-30. |
| 2021-06-03 | Geneos Therapeutics | Results Geneos Therapeutics Announces Clinical Updates on Personalized Cancer Vaccine Program geneostx.com ↗
The treatment was generally safe and well tolerated with no treatment related serious adverse events noted on the trial. |
All press releases naming this drug 7 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GNOS-PV02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04251117 ↗ |
| Modality | Vaccine | “personalized neoantigen DNA vaccine (GNOS-PV02)” NCT07722741 ↗ |
| Route | Other | “delivered by intradermal injection and electroporation” NCT07722741 ↗ |